参考文献/References:
[1]Bartalena L, Kahaly GJ, Baldeschi L, et al.The 2021 European Group on Graves′ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves′ orbitopathy[J]. Eur J Endocrinol, 2021,185(4): G4367. [2]Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy[J]. Nat Rev Endocrinol, 2020, 16(2):104116. [3]Wiersinga WM, Regensburg NI, Mourits MP. Differential involvement of orbital fat and extraocular muscles in graves′ ophthalmopathy[J]. Eur Thyroid J, 2013, 2(1):1421.[4]Xu L, Li L, Xie C, et al.Thickness of Extraocular Muscle and Orbital Fat in MRI Predicts Response to Glucocorticoid Therapy in Graves′ Ophthalmopathy[J]. Int J Endocrinol, 2017, 2017: 3196059. [5]Song K, Wang S, Mani M, et al.Wnt signaling, de novo lipogenesis, adipogenesis and ectopic fat[J]. Oncotarget, 2014, 5(22):1100011003. [6]Xiao X, Li H, Yang J, et al. wnt/βcatenin signaling pathway and lipolysis enzymes participate in methylprednisolone induced fat differential distribution between subcutaneous and visceral adipose tissue[J]. Steroids, 2014, 84:3035. [7]Zhang W, Drake MT. Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis[J]. Curr Osteoporos Rep, 2012, 10(1):93100.[8]Niehrs C．Function and biological roles of the Dickkopf family of wnt modulators[J]．0ncogene， 2006， 25(57):74697481.[9]Bartalena L, Baldeschi L, Dickinson AJ, et al.Consensus statement of the European group on Graves orbitopathy (EUGOGO) on management of Graves orbitopathy[J]. Thyroid, 2008, 18(3):333346. [10]Holzem M, Boutros M, Holstein TW. The origin and evolution of Wnt signalling[J]. Nat Rev Genet, 2024, 25(7):500512.[11]Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol Cancer, 2022, 21(1):144.[12]周凯, 周文泉. Wnt信号通路抑制因子SFRPs在肿瘤发生发展中的研究进展[J]. 医学研究生学报, 2012, 25(9):9971001.[13]王震凯,朱人敏.Wnt信号转导通路在肿瘤中的研究进展[J].医学研究生学报,2007,20(12):12941297.[14]Hu L, Chen W, Qian A, et al.Wnt/betacatenin signaling components and mechanisms in bone formation, homeostasis, and disease[J]. Bone Res, 2024,12(1):39.[15]Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling[J]. Science, 2000, 289(5481):950953.[16]Kim HY, Jang HJ, Muthamil S,et al. Novel insights into regulators and functional modulators of adipogenesis[J].Biomed Pharmacother, 2024, 177:117073.[17]Li Y, Yao L, Lu J. IL35 inhibits adipogenesis via PPARγWnt/βcatenin signaling pathway by targeting Axin2[J]. Int Immunopharmacol, 2023, 122: 110615.[18]Bahn RS. Current Insights into the Pathogenesis of Graves′ Ophthalmopathy[J]. Horm Metab Res, 2015, 47(10):773778.[19]Kim DW, Taneja K, Hoang T, et al. Transcriptomic Profiling of Control and ThyroidAssociated Orbitopathy (TAO) Orbital Fat and TAO Orbital Fibroblasts Undergoing Adipogenesis[J]. Invest Ophthalmol Vis Sci, 2021, 62(9):24.[20]Tao W, AyalaHaedo JA, Field MG, et al. RNAsequencing gene expression profiling of orbital adiposederived stem cell population implicate HOX genes and WNT signaling dysregulation in the pathogenesis of thyroidassociated orbitopathy[J]. Invest Ophthalmol Vis Sci, 2017, 58(14):61466158.[21]Ezra DG, Krell J, Rose GE, et al.Transcriptomelevel microarray expression profiling implicates IGF1 and Wnt signalling dysregulation in the pathogenesis of thyroidassociated orbitopathy[J]. J Clin Pathol, 2012, 65(7):608613.[22]Kumar S, Leontovich A, Coenen MJ, et al. Gene expression profiling of orbital adipose tissue from patients with Graves′ ophthalmopathy: a potential role for secreted frizzledrelated protein1 in orbital adipogenesis[J].J Clin Endocrinol Metab, 2005, 90(8):47304735.[23]Jung SJ, Choi YJ, Park TK, et al. Wnt signalling inhibits adipogenesis in orbital fibroblasts from patients with Graves′ orbitopathy[J]. Br J Ophthalmol, 2021, 106(7):10191027.[24]Lee BW, Kumar VB, Biswas P, et al. Transcriptome analysis of orbital adipose tissue in active thyroid eye disease using next generation RNA sequencing technology[J]. Open Ophthalmol J, 2018, 12:4152.